NCCN Guidelines® Insights - Hodgkin Lymphoma, Version 2.2022
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Hodgkin Lymphoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Hodgkin Lymphoma
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Richard T. Hoppe, MD, Panel Chair
Leo I. Gordon, MD, Panel Member
Monika Metzger, MD, Panel Member
Jennifer Burns, Manager, Guidelines Support, NCCN
Mallory Campbell, PhD, Oncology Scientist/Medical Writer, NCCN
Hema Sundar, PhD, Manager, Global Clinical Content, NCCN
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Ranjana H. Advani, MD, Panel Vice Chair, consulting fees from Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., Gilead Sciences, Inc., Incyte Corporation, Roche Laboratories, Inc., and sanofi-aventis U.S.; and grant/research support from Forty Seven, Inc.; Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Cytier Therapeutics, Pharmacyclics, Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.
Philippe Armand, MD, PhD, Panel Member, scientific advisor for ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, C4 Therapeutics, Epizyme, Genentech, Inc., Genmab, Merck & Co., Inc., and Regeneron Pharmaceuticals; grant/research support from Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Genentech, Inc., and IGM Biosciences, Kite; consulting fees from ADC Therapeutics, Enterome, Merck & Co., Inc., and Xencor; honorarium from Merck & Co.; and steering committee member for Tessa Therapeutics.
Alex F. Herrera, MD, Panel Member, consulting fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Regeneron Pharmaceuticals, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and grant/research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Gilead Sciences, Inc., Kite Pharma, Merck & Co., Inc., and Seattle Genetics, Inc.
Randa Tao, MD, Panel Member, consulting fees from Helsinn Therapeutics Inc., QED Therapeutics, Inc., and The Lynx Group, LLC.
Jane N. Winter, MD, Panel Member, honoraria from Celgene Corporation, Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Actinium Pharmaceuticals, Inc., and Epizyme; consulting fees from Novartis Pharmaceuticals Corporation and CVS Pharmacy; and grant/research support from Merck & Co., Inc.
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-22-004-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation